;PMID: 7488231
;source_file_831.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..216] = [t:51..216]
;2)section:[e:220..264] = [t:220..264]
;3)section:[e:268..381] = [t:268..381]
;4)sentence:[e:385..514] = [t:385..514]
;5)sentence:[e:515..770] = [t:515..770]
;6)sentence:[e:771..897] = [t:771..897]
;7)sentence:[e:898..1010] = [t:898..1010]
;8)sentence:[e:1011..1229] = [t:1011..1229]
;9)sentence:[e:1230..1316] = [t:1230..1316]
;10)sentence:[e:1317..1534] = [t:1317..1534]
;11)sentence:[e:1535..1649] = [t:1535..1649]
;12)sentence:[e:1650..1878] = [t:1650..1878]
;13)sentence:[e:1879..2063] = [t:1879..2063]
;14)section:[e:2067..2111] = [t:2067..2110]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:2067..2111][t:2067..2110]
;Token/POS Errors
;ERROR_Token in entity file but not tree[2110..2111] ]

;section 0 Span:0..45
;Biochem Pharmacol. 1995 Oct 12;50(8):1171-80.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (,:[17..18] .)
        (CD:[19..23] 1995) (NNP:[24..27] Oct) (CD:[28..34] 12;50-LRB-)
        (CD:[34..35] 8) (JJ:[35..36] -RRB-) (CD:[36..41] :1171)
        (HYPH:[41..42] -) (CD:[42..44] 80) (.:[44..45] .)))

;sentence 1 Span:51..216
;Modulation by benzo[a]pyrene of epidermal growth factor receptors, cell 
;proliferation, and secretion of human chorionic gonadotropin in human
;placental  cell lines.
;[65..79]:substance:"benzo[a]pyrene"
;[83..116]:substance:"epidermal growth factor receptors"
;[156..184]:substance:"human chorionic gonadotropin"
(SENT
  (NP-HLN
    (NP (NN:[51..61] Modulation))
    (PP (IN:[62..64] by)
      (NP (NN:[65..79] benzo-LSB-a-RSB-pyrene)))
    (PP (IN:[80..82] of)
      (NP
        (NP (JJ:[83..92] epidermal)
          (NML (NN:[93..99] growth) (NN:[100..106] factor))
          (NNS:[107..116] receptors))
        (,:[116..117] ,)
        (NP (NN:[118..122] cell) (NN:[124..137] proliferation))
        (,:[137..138] ,) (CC:[139..142] and)
        (NP
          (NP (NN:[143..152] secretion))
          (PP (IN:[153..155] of)
            (NP (JJ:[156..161] human) (JJ:[162..171] chorionic)
                (NN:[172..184] gonadotropin))))))
    (PP-LOC (IN:[185..187] in)
      (NP (JJ:[188..193] human) (JJ:[194..203] placental) (NN:[205..209] cell)
          (NNS:[210..215] lines)))
    (.:[215..216] .)))

;section 2 Span:220..264
;Zhang L, Connor EE, Chegini N, Shiverick KT.
(SEC
  (FRAG (NNP:[220..225] Zhang) (NNP:[226..228] L,) (NNP:[229..235] Connor)
        (NNP:[236..238] EE) (,:[238..239] ,) (NNP:[240..247] Chegini)
        (NNP:[248..249] N) (,:[249..250] ,) (NNP:[251..260] Shiverick)
        (NNP:[261..264] KT.)))

;section 3 Span:268..381
;Department of Pharmacology and Therapeutics, College of Medicine, University
;of  Florida, Gainesville 32610, USA.
(SEC
  (FRAG (NNP:[268..278] Department) (IN:[279..281] of)
        (NNP:[282..294] Pharmacology) (CC:[295..298] and)
        (NNP:[299..311] Therapeutics) (,:[311..312] ,) (NNP:[313..320] College)
        (IN:[321..323] of) (NNP:[324..332] Medicine) (,:[332..333] ,)
        (NNP:[334..344] University) (IN:[345..347] of) (NNP:[349..356] Florida)
        (,:[356..357] ,) (NNP:[358..369] Gainesville) (CD:[370..375] 32610)
        (,:[375..376] ,) (NNP:[377..380] USA) (.:[380..381] .)))

;sentence 4 Span:385..514
;Clinical observations indicate that maternal cigarette smoking has
;significant  detrimental effects on fetoplacental development.
(SENT
  (S
    (NP-SBJ (JJ:[385..393] Clinical) (NNS:[394..406] observations))
    (VP (VBP:[407..415] indicate)
      (SBAR (IN:[416..420] that)
        (S
          (NP-SBJ (JJ:[421..429] maternal) (NN:[430..439] cigarette)
                  (NN:[440..447] smoking))
          (VP (VBZ:[448..451] has)
            (NP
              (NP (JJ:[452..463] significant) (JJ:[465..476] detrimental)
                  (NNS:[477..484] effects))
              (PP (IN:[485..487] on)
                (NP (JJ:[488..501] fetoplacental) (NN:[502..513] development))))))))
    (.:[513..514] .)))

;sentence 5 Span:515..770
;The present study used human  trophoblastic choriocarcinoma cell lines of
;placental origin to investigate the  effects of benz[a]pyrene (BaP) on
;epidermal growth factor (EGF) receptors, cell  proliferation and human
;chorionic gonadotropin (hCG) secretion.
;[637..650]:substance:"benz[a]pyrene"
;[652..655]:substance:"BaP"
;[660..699]:substance:"epidermal growth factor (EGF) receptors"
;[725..753]:substance:"human chorionic gonadotropin"
;[755..758]:substance:"hCG"
(SENT
  (S
    (NP-SBJ (DT:[515..518] The) (JJ:[519..526] present) (NN:[527..532] study))
    (VP (VBD:[533..537] used)
      (NP
        (NP (JJ:[538..543] human) (JJ:[545..558] trophoblastic)
            (NN:[559..574] choriocarcinoma) (NN:[575..579] cell)
            (NNS:[580..585] lines))
        (PP (IN:[586..588] of)
          (NP (JJ:[589..598] placental) (NN:[599..605] origin))))
      (S-PRP
        (NP-SBJ (-NONE-:[605..605] *))
        (VP (TO:[606..608] to)
          (VP (VB:[609..620] investigate)
            (NP
              (NP (DT:[621..624] the) (NNS:[626..633] effects))
              (PP (IN:[634..636] of)
                (NP
                  (NP (NN:[637..650] benz-LSB-a-RSB-pyrene))
                  (NP (-LRB-:[651..652] -LRB-) (NN:[652..655] BaP)
                      (-RRB-:[655..656] -RRB-))))
              (PP (IN:[657..659] on)
                (NP
                  (NP
                    (NML
                      (NML (JJ:[660..669] epidermal) (NN:[670..676] growth)
                           (NN:[677..683] factor))
                      (NML (-LRB-:[684..685] -LRB-) (NN:[685..688] EGF)
                           (-RRB-:[688..689] -RRB-)))
                    (NNS:[690..699] receptors))
                  (,:[699..700] ,)
                  (NP (NN:[701..705] cell) (NN:[707..720] proliferation))
                  (CC:[721..724] and)
                  (NP
                    (NML
                      (NML (JJ:[725..730] human) (JJ:[731..740] chorionic)
                           (NN:[741..753] gonadotropin))
                      (NML (-LRB-:[754..755] -LRB-) (NN:[755..758] hCG)
                           (-RRB-:[758..759] -RRB-)))
                    (NN:[760..769] secretion)))))))))
    (.:[769..770] .)))

;sentence 6 Span:771..897
;BaP decreased  125I-EGF binding and EGF receptor protein in a
;concentration-related manner in  both BeWo and JEG-3 cell lines.
;[771..774]:substance:"BaP"
;[786..790]:substance:"125I"
;[791..794]:substance:"EGF"
;[807..827]:substance:"EGF receptor protein"
(SENT
  (S
    (NP-SBJ (NN:[771..774] BaP))
    (VP (VBD:[775..784] decreased)
      (NP
        (NP
          (NML (NN:[786..790] 125I) (HYPH:[790..791] -) (NN:[791..794] EGF))
          (NN:[795..802] binding))
        (CC:[803..806] and)
        (NP (NN:[807..810] EGF) (NN:[811..819] receptor) (NN:[820..827] protein)))
      (PP-MNR (IN:[828..830] in)
        (NP (DT:[831..832] a)
          (ADJP (NN:[833..846] concentration) (HYPH:[846..847] -)
                (JJ:[847..854] related))
          (NN:[855..861] manner)))
      (PP (IN:[862..864] in)
        (NP (CC:[866..870] both)
          (NP
            (NP (NN:[871..875] BeWo)
              (NML-1 (-NONE-:[875..875] *P*)))
            (CC:[876..879] and)
            (NP (NN:[880..885] JEG-3)
              (NML-1 (NN:[886..890] cell) (NNS:[891..896] lines)))))))
    (.:[896..897] .)))

;sentence 7 Span:898..1010
;The steady-state level of EGF receptor mRNA,  however, was not changed
;significantly by BaP in either cell line.
;[924..941]:substance:"EGF receptor mRNA"
;[986..989]:substance:"BaP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[898..901] The)
        (NML (JJ:[902..908] steady) (HYPH:[908..909] -) (NN:[909..914] state))
        (NN:[915..920] level))
      (PP (IN:[921..923] of)
        (NP
          (NML (NN:[924..927] EGF) (NN:[928..936] receptor))
          (NN:[937..941] mRNA))))
    (,:[941..942] ,)
    (ADVP (RB:[944..951] however))
    (,:[951..952] ,)
    (VP (VBD:[953..956] was) (RB:[957..960] not)
      (VP (VBN:[961..968] changed)
        (NP-1 (-NONE-:[968..968] *))
        (ADVP (RB:[969..982] significantly))
        (PP (IN:[983..985] by)
          (NP-LGS (NN:[986..989] BaP)))
        (PP (IN:[990..992] in)
          (NP (DT:[993..999] either) (NN:[1000..1004] cell)
              (NN:[1005..1009] line)))))
    (.:[1009..1010] .)))

;sentence 8 Span:1011..1229
;Cell  proliferation was unchanged or slightly increased following exposure to
;10 and  50 microM BaP in the presence of serum, whereas proliferation
;progressively  decreased in cells exposed under serum-free conditions.
;[1089..1091]:quantitative-value:"10"
;[1097..1099]:quantitative-value:"50"
;[1100..1106]:quantitative-units:"microM"
;[1107..1110]:substance:"BaP"
(SENT
  (S
    (NP-SBJ (NN:[1011..1015] Cell) (NN:[1017..1030] proliferation))
    (VP (VBD:[1031..1034] was)
      (ADJP-PRD
        (ADJP (JJ:[1035..1044] unchanged))
        (CC:[1045..1047] or)
        (ADJP (RB:[1048..1056] slightly) (JJ:[1057..1066] increased)))
      (S-ADV
        (NP-SBJ (-NONE-:[1066..1066] *))
        (VP (VBG:[1067..1076] following)
          (NP (NN:[1077..1085] exposure)
            (PP (TO:[1086..1088] to)
              (NP
                (NP
                  (NML (CD:[1089..1091] 10)
                    (NML-1 (-NONE-:[1091..1091] *P*)))
                  (NML-2 (-NONE-:[1091..1091] *P*)))
                (CC:[1092..1095] and)
                (NP
                  (NML (CD:[1097..1099] 50)
                    (NML-1 (NN:[1100..1106] microM)))
                  (NML-2 (NN:[1107..1110] BaP))))))
          (PP (IN:[1111..1113] in)
            (NP
              (NP (DT:[1114..1117] the) (NN:[1118..1126] presence))
              (PP (IN:[1127..1129] of)
                (NP (NN:[1130..1135] serum)))))))
      (,:[1135..1136] ,)
      (SBAR-ADV (DT:[1137..1144] whereas)
        (S
          (NP-SBJ (NN:[1145..1158] proliferation))
          (VP
            (ADVP (RB:[1159..1172] progressively))
            (VBD:[1174..1183] decreased)
            (PP-LOC (IN:[1184..1186] in)
              (NP
                (NP (NNS:[1187..1192] cells))
                (VP (VBN:[1193..1200] exposed)
                  (NP (-NONE-:[1200..1200] *))
                  (PP-MNR (IN:[1201..1206] under)
                    (NP
                      (ADJP (NN:[1207..1212] serum) (HYPH:[1212..1213] -)
                            (JJ:[1213..1217] free))
                      (NNS:[1218..1228] conditions))))))))))
    (.:[1228..1229] .)))

;sentence 9 Span:1230..1316
;The mitogenic effect of  EGF was inhibited by cotreatment with BaP in both
;cell lines.
;[1255..1258]:substance:"EGF"
;[1293..1296]:substance:"BaP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1230..1233] The) (JJ:[1234..1243] mitogenic)
          (NN:[1244..1250] effect))
      (PP (IN:[1251..1253] of)
        (NP (NN:[1255..1258] EGF))))
    (VP (VBD:[1259..1262] was)
      (VP (VBN:[1263..1272] inhibited)
        (NP-1 (-NONE-:[1272..1272] *))
        (PP-MNR (IN:[1273..1275] by)
          (NP
            (NP (NN:[1276..1287] cotreatment))
            (PP (IN:[1288..1292] with)
              (NP (NN:[1293..1296] BaP)))))
        (PP-LOC (IN:[1297..1299] in)
          (NP (DT:[1300..1304] both) (NN:[1305..1309] cell)
              (NNS:[1310..1315] lines)))))
    (.:[1315..1316] .)))

;sentence 10 Span:1317..1534
;Further study of  trophoblast endocrine function showed that both basal and
;EGF-stimulated  secretion of hCG was reduced significantly by BaP exposure in
;BeWo cells,  whereas no adverse effect was seen in JEG-3 cells.
;[1393..1396]:substance:"EGF"
;[1422..1425]:substance:"hCG"
;[1455..1458]:substance:"BaP"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1317..1324] Further) (NN:[1325..1330] study))
      (PP (IN:[1331..1333] of)
        (NP (NN:[1335..1346] trophoblast) (NN:[1347..1356] endocrine)
            (NN:[1357..1365] function))))
    (VP (VBD:[1366..1372] showed)
      (SBAR (IN:[1373..1377] that)
        (S
          (NP-SBJ-2
            (NP (CC:[1378..1382] both)
              (NP (JJ:[1383..1388] basal)
                (NML-1 (-NONE-:[1388..1388] *P*)))
              (CC:[1389..1392] and)
              (NP
                (ADJP (NN:[1393..1396] EGF) (HYPH:[1396..1397] -)
                      (VBN:[1397..1407] stimulated))
                (NML-1 (NN:[1409..1418] secretion))))
            (PP (IN:[1419..1421] of)
              (NP (NN:[1422..1425] hCG))))
          (VP (VBD:[1426..1429] was)
            (VP (VBN:[1430..1437] reduced)
              (NP-2 (-NONE-:[1437..1437] *))
              (ADVP (RB:[1438..1451] significantly))
              (PP (IN:[1452..1454] by)
                (NP-LGS (NN:[1455..1458] BaP) (NN:[1459..1467] exposure)))
              (PP-LOC (IN:[1468..1470] in)
                (NP (NN:[1471..1475] BeWo) (NNS:[1476..1481] cells)))
              (,:[1481..1482] ,)
              (SBAR-ADV (IN:[1484..1491] whereas)
                (S
                  (NP-SBJ-3 (DT:[1492..1494] no) (JJ:[1495..1502] adverse)
                            (NN:[1503..1509] effect))
                  (VP (VBD:[1510..1513] was)
                    (VP (VBN:[1514..1518] seen)
                      (NP-3 (-NONE-:[1518..1518] *))
                      (PP-LOC (IN:[1519..1521] in)
                        (NP (NN:[1522..1527] JEG-3) (NNS:[1528..1533] cells))))))))))))
    (.:[1533..1534] .)))

;sentence 11 Span:1535..1649
;Finally, cytochrome P450 1A1  (CYP1A1) was induced in a
;concentration-dependent manner by BaP in both cell  lines.
;[1544..1563]:cyp450:"cytochrome P450 1A1"
;[1566..1572]:cyp450:"CYP1A1"
;[1625..1628]:substance:"BaP"
(SENT
  (S
    (ADVP (RB:[1535..1542] Finally))
    (,:[1542..1543] ,)
    (NP-SBJ-1
      (NP (NN:[1544..1554] cytochrome) (NN:[1555..1559] P450)
          (NN:[1560..1563] 1A1))
      (NP (-LRB-:[1565..1566] -LRB-) (NN:[1566..1572] CYP1A1)
          (-RRB-:[1572..1573] -RRB-)))
    (VP (VBD:[1574..1577] was)
      (VP (VBN:[1578..1585] induced)
        (NP-1 (-NONE-:[1585..1585] *))
        (PP-MNR (IN:[1586..1588] in)
          (NP (DT:[1589..1590] a)
            (ADJP (NN:[1591..1604] concentration) (HYPH:[1604..1605] -)
                  (JJ:[1605..1614] dependent))
            (NN:[1615..1621] manner)))
        (PP (IN:[1622..1624] by)
          (NP-LGS (NN:[1625..1628] BaP)))
        (PP (IN:[1629..1631] in)
          (NP (DT:[1632..1636] both) (NN:[1637..1641] cell)
              (NNS:[1643..1648] lines)))))
    (.:[1648..1649] .)))

;sentence 12 Span:1650..1878
;Thus, data indicate that the BaP-mediated loss of EGF receptors alters 
;trophoblast proliferation and endocrine function, and that different
;mechanisms  may be involved in the regulation of hCG secretion in BeWo and
;JEG-3 cells.
;[1679..1682]:substance:"BaP"
;[1700..1713]:substance:"EGF receptors"
;[1840..1843]:substance:"hCG"
(SENT
  (S
    (ADVP (RB:[1650..1654] Thus))
    (,:[1654..1655] ,)
    (NP-SBJ (NNS:[1656..1660] data))
    (VP (VBP:[1661..1669] indicate)
      (SBAR
        (SBAR (IN:[1670..1674] that)
          (S
            (NP-SBJ
              (NP (DT:[1675..1678] the)
                (ADJP (NN:[1679..1682] BaP) (HYPH:[1682..1683] -)
                      (VBN:[1683..1691] mediated))
                (NN:[1692..1696] loss))
              (PP (IN:[1697..1699] of)
                (NP (NN:[1700..1703] EGF) (NNS:[1704..1713] receptors))))
            (VP (VBZ:[1714..1720] alters)
              (NP
                (NP (NN:[1722..1733] trophoblast)
                    (NN:[1734..1747] proliferation))
                (CC:[1748..1751] and)
                (NP (NN:[1752..1761] endocrine) (NN:[1762..1770] function))))))
        (,:[1770..1771] ,) (CC:[1772..1775] and)
        (SBAR (IN:[1776..1780] that)
          (S
            (NP-SBJ-2 (JJ:[1781..1790] different) (NNS:[1791..1801] mechanisms))
            (VP (MD:[1803..1806] may)
              (VP (VB:[1807..1809] be)
                (VP (JJ:[1810..1818] involved)
                  (NP-2 (-NONE-:[1818..1818] *))
                  (PP-CLR (IN:[1819..1821] in)
                    (NP
                      (NP (DT:[1822..1825] the) (NN:[1826..1836] regulation))
                      (PP (IN:[1837..1839] of)
                        (NP (NN:[1840..1843] hCG) (NN:[1844..1853] secretion)))))
                  (PP-LOC (IN:[1854..1856] in)
                    (NP
                      (NP (NN:[1857..1861] BeWo)
                        (NML-1 (-NONE-:[1861..1861] *P*)))
                      (CC:[1862..1865] and)
                      (NP (NN:[1866..1871] JEG-3)
                        (NML-1 (NNS:[1872..1877] cells))))))))))))
    (.:[1877..1878] .)))

;sentence 13 Span:1879..2063
;In  addition, this study supports the feasibility of using the BeWo and JEG-3
; trophoblastic choriocarcinoma cell lines to investigate biomarkers and 
;mechanisms of placental toxicity.
(SENT
  (S
    (PP (IN:[1879..1881] In)
      (NP (NN:[1883..1891] addition)))
    (,:[1891..1892] ,)
    (NP-SBJ (DT:[1893..1897] this) (NN:[1898..1903] study))
    (VP (VBZ:[1904..1912] supports)
      (NP
        (NP (DT:[1913..1916] the) (NN:[1917..1928] feasibility))
        (PP (IN:[1929..1931] of)
          (S-NOM
            (NP-SBJ (-NONE-:[1931..1931] *))
            (VP (VBG:[1932..1937] using)
              (NP (DT:[1938..1941] the)
                (NML
                  (NML (NN:[1942..1946] BeWo)
                    (NML-1 (-NONE-:[1946..1946] *P*)))
                  (CC:[1947..1950] and)
                  (NML (NN:[1951..1956] JEG-3)
                    (NML-1 (JJ:[1958..1971] trophoblastic)
                           (NN:[1972..1987] choriocarcinoma)
                           (NN:[1988..1992] cell) (NNS:[1993..1998] lines)))))
              (S-ADV
                (NP-SBJ (-NONE-:[1998..1998] *))
                (VP (TO:[1999..2001] to)
                  (VP (VB:[2002..2013] investigate)
                    (NP
                      (NP (NNS:[2014..2024] biomarkers) (CC:[2025..2028] and)
                          (NNS:[2030..2040] mechanisms))
                      (PP (IN:[2041..2043] of)
                        (NP (JJ:[2044..2053] placental)
                            (NN:[2054..2062] toxicity))))))))))))
    (.:[2062..2063] .)))

;section 14 Span:2067..2110
;PMID: 7488231 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[2067..2071] PMID) (::[2071..2072] :) (CD:[2073..2080] 7488231)
        (-LRB-:[2081..2082] -LSB-) (NNP:[2082..2088] PubMed)
        (HYPH:[2089..2090] -) (NN:[2091..2098] indexed) (IN:[2099..2102] for)
        (NNP:[2103..2110] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2110..EOF] ]

(ORPH -RSB-)
